Frontlight ResearchEarly access
TerminatedNo phase
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
Key facts
- Who runs it
- Azienda USL Reggio Emilia - IRCCS
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 81 people enrolled
- Started
- 29 Jun 2020
- Ended
- 30 Jun 2025
- Type of study
- Observational, 3 groups
- Record updated
- 11 September 2025
- Why it stopped
- Healted Prematurely
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (6)Hide the full registry criteria
Who can take part
- signing informed consent, in case of patients still alive
- histologically confirmed diagnosis of metastatic renal cell carcinoma
- at least one administration of Nivolumab therapy, in the second-or third line of treatment february 2017 to December 31, 2018
- availability of inpatient and/or outpatient medical records for clinical data collection
Who cannot take part
- patients who have received immunotherapy under EAP (Expanded Access Programm) or other clinical trials
- dialysis patients
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an observational, retrospective, multicenter study aimed to compare the toxicity of Nivolumab in patients with metastatic renal cell carcinoma treated in line II and III stratified into 3 patient groups:
Read full original descriptionShow less
* patients with normal or mildly reduced renal function (GFR<90 and ≥60 ml/min/1.73 m\^2); * patients with moderate renal impairment (GFR <60 e ≥30 ml/min/1.73 m\^2), * patients with severe renal impairment (GFR <30 e ≥15 ml/min/1.73 m\^2) Patients must have been treated with Nivolumab, as per clinical practice. All patients who have received at least one drug administration between february 2017 to December 31, 2018 will be enrolled in the study.
The 3 groups in the trial
- Patients with normal or mildly reduced renal function (GFR<90 and ≥60 ml/min/1.73 m^2)
- Patients with moderate renal failure (GFR <60 e ≥30 ml/min/1.73 m^2)
- Patients with severe renal failure (GFR <30 e ≥15 ml/min/1.73 m^2)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Retrospective Observational Study on the Safety of Nivolumab in Patients With Metastatic Renal Carcinoma and Renal Failure
- Record updated
- 11 September 2025